Exact Sciences(EXAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EXAS Exact Sciences

Trading 01-12 12:33:57 EST

102.08

-0.03

-0.03%

High102.41	Low102.02	Vol672.48K
Open102.02	D1 Closing102.11	Amplitude0.38%
Mkt Cap19.37B	Tradable Cap19.14B	Total Shares189.77M
T/O68.69M	T/O Rate0.36%	Tradable Shares187.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EXAS","market":"US","secType":"STK","nameCN":"Exact Sciences","latestPrice":102.08,"timestamp":1768239231373,"preClose":102.11,"halted":0,"volume":672477,"delay":0,"floatShares":187461719,"shares":189765827,"eps":-5.263769,"marketStatus":"Trading","change":-0.03,"latestTime":"01-12 12:33:57 EST","open":102.02,"high":102.41,"low":102.02,"amount":68687473.257,"amplitude":0.003819,"askPrice":102.09,"askSize":392,"bidPrice":102.08,"bidSize":350,"shortable":3,"etf":0,"ttmEps":-5.263769,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768251600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":980917200000,"exchange":"NASDAQ","adjPreClose":102.11,"preHourTrading":{"tag":"盘前","latestPrice":101.95,"preClose":102.11,"latestTime":"09:29 EST","volume":1722,"amount":175549.420872,"timestamp":1768228199999},"postHourTrading":{"tag":"盘后","latestPrice":102.07,"preClose":102.11,"latestTime":"18:49 EST","volume":16814,"amount":1715712.1526,"timestamp":1768002540470},"volumeRatio":0.504288,"impliedVol":0.0744,"impliedVolPercentile":0.0199},"requestUrl":"/m/hq/s/EXAS/wiki","defaultTab":"wiki","newsList":[{"id":"2602872510","title":"Press Release: MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2602872510","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602872510?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences. IRVINE, CA -- January 12, 2026  -- MDxHealth SA  , a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2025 revenues and issued 2026 revenue guidance.The Company is also issuing 2026 revenue guidance of $137-140 million, which represents year-over-year growth of 26-28%.Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAS","MDXH"],"gpt_icon":0},{"id":"2602830682","title":"Clinical Labs Hope to Head Off Looming Medicare Cuts -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2602830682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602830682?lang=en_us&edition=fundamental","pubTime":"2026-01-10 03:24","pubTimestamp":1767986640,"startTime":"0","endTime":"0","summary":"U.S. House representatives heard the clinical lab industry plead yesterday for a reprieve from looming cuts as large as 15% in what Medicare pays Labcorp Holdings, Quest Diagnostics and cancer-testing specialists like Guardant Health, Exact Sciences, and Natera.Starting February, a current law will require labs to tell Medicare the rates that private insurers paid for tests back in 2019. Medicare will then cut its own test payments to those levels in 2027.That will hurt the development of technologies like the genomic tests now used for diagnosing cancer patients and sick infants, said American Clinical Laboratory Association President Susan Van Meter, at a Thursday hearing on Medicare reimbursement rates.The February deadline exists because of a law passed 10 years ago that made clinical labs the only healthcare industry whose Medicare rates would match those paid by private insurers. Commercial rates were first surveyed in 2016 and Medicare cut its test payments by up to 10% in each ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU0823417737.USD","BK4548","LU0823417653.USD","LU2324357040.USD","LU1059921491.USD","LU1854104046.USD","LU0251131958.USD","BK4551","BK4211","BK4139","LU1861558580.USD","LU0266013472.USD","LU2506951875.HKD","LU0742534661.SGD","LU2506952170.USD","BK4567","LU0048573561.USD","LU1854103824.USD","BK4196","BK4550","EXAS","DGX","GH","LU0950375773.USD","LH","LU1861559042.SGD","LU0251142724.SGD","LU2237438978.USD","LU2506951958.HKD","BK4588","LU2506952097.USD","BK4585","HOPE","BK4535","LU0006061336.USD"],"gpt_icon":0},{"id":"2602371882","title":"Exact Sciences Sets February 20, 2026 Virtual Meeting for Shareholder Vote on $105-per-Share Abbott Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2602371882","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602371882?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:50","pubTimestamp":1767966604,"startTime":"0","endTime":"0","summary":"New activity is brewing for Exact Sciences ( ($EXAS) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vot...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exact-sciences-sets-february-20-2026-virtual-meeting-for-shareholder-vote-on-105-per-share-abbott-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exact-sciences-sets-february-20-2026-virtual-meeting-for-shareholder-vote-on-105-per-share-abbott-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2112291526.USD","LU1989763690.USD","LU2133065610.SGD","LU0868494617.USD","LU1989763427.SGD","ABT","SG9999002232.USD","BK4533","LU2089984988.USD","SG9999002224.SGD","BK4568","SGXZ23171101.USD","LU0122379950.USD","LU0170899867.USD","LU0289739699.SGD","BK4588","LU2211815571.USD","LU1914381329.SGD","LU1691799644.USD","LU1721429741.USD","BK4581","LU1057294990.SGD","LU2237957902.USD","LU0058720904.USD","LU0266013472.USD","BK4592","LU1721429402.USD","BK4082","LU1861559042.SGD","EXAS","LU1861558580.USD","LU1061106388.HKD","LU2324357040.USD","BK4504","BK4548","LU2237957811.SGD","LU0882574055.USD","LU0234572021.USD","BK4139","IE0002141913.USD","SGXZ41872573.SGD","BK4566","SG9999004303.SGD","BK4585","LU2468319806.SGD","IE0009355771.USD","LU1023059063.AUD","LU0114720955.EUR","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2601396688","title":"Exact Sciences Cut to In-Line From Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2601396688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601396688?lang=en_us&edition=fundamental","pubTime":"2026-01-06 02:09","pubTimestamp":1767636540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EXAS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 13:09 ET (18:09 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAS"],"gpt_icon":0},{"id":"2595725705","title":"It’s Earnings Warning Season. How to Profit From Others’ Misery","url":"https://stock-news.laohu8.com/highlight/detail?id=2595725705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595725705?lang=en_us&edition=fundamental","pubTime":"2026-01-01 23:00","pubTimestamp":1767279600,"startTime":"0","endTime":"0","summary":"January is an optimistic time of year for investors, but not necessarily for corporate America.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9c084b36ba0e1e4ad2a94bff2fcea0b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANF","LU0058720904.USD","FIVE","BK4200","LU0823411888.USD","BK4534","LU2468319806.SGD","REGN","TMUS","BK4139","BK4548","IPAR","LULU","QDEL","LU0114720955.EUR","LU0823434740.USD","LU2362540622.SGD","LU2362541513.USD","HOLX","NVCR","LU1974910355.USD","ALNY","LU2023250504.SGD","STAA","BK4202","DXCM","BK4585","LU0889565916.HKD","LU0320765992.SGD","LU0289739699.SGD","BK4588","GMED","LU0109394709.USD","PCRX","PTCT","FOLD","SLAB","BK4121","LU1917777945.USD","LU0882574055.USD","ORC","CDNA","LU0053666078.USD","LU0823434583.USD","EXAS","LU2237438978.USD","BK4094","AEO","HALO","ILMN","LU2089984988.USD","BK4535","LU2106854487.HKD","LU0823416689.USD","LU1496350502.SGD","IDCC","LU2362541273.HKD","DHR","BK4504"],"gpt_icon":0},{"id":"2595540713","title":"ADVISORY-Alert from law firm on Exact Sciences-Abbott deal withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2595540713","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595540713?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:48","pubTimestamp":1767106098,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert from law firm on Exact Sciences-Abbott deal withdrawnAn alert on Exact Sciences EXAS.O regarding its proposed sale to Abbott Laboratories ABT.N was inadvertently published from a law fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nTUA2FVHCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","SG9999004303.SGD","LU1721429402.USD","SGXZ41872573.SGD","LU2089984988.USD","EXAS","IE00BJT1NW94.SGD","LU0234572021.USD","LU2237957902.USD","BK4592","IE00B4R5TH58.HKD","LU1914381329.SGD","LU0266013472.USD","LU0170899867.USD","ABT","BK4585","LU1023059063.AUD","LU1861558580.USD","BK4504","LU1989763427.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4568","BK4588","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU1989763690.USD","LU2468319806.SGD","LU2324357040.USD","BK4566","SG9999002232.USD","LU0289739699.SGD","BK4548","LU1861559042.SGD","LU1721429741.USD","LU1691799644.USD","LU2112291526.USD","BK4082","IE0002141913.USD","LU2211815571.USD","LU0868494617.USD","LU0058720904.USD","LU1057294990.SGD","LU0114720955.EUR","BK4533","LU2237957811.SGD","LU0882574055.USD","IE0009355771.USD","SG9999002224.SGD","BK4139"],"gpt_icon":0},{"id":"2595718258","title":"Exact Sciences Shareholders Unhappy With $105 per Share Sale to Abbott Should Contact Julie & Holleman Llp Regarding Potential Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2595718258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595718258?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:31","pubTimestamp":1767105104,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nTUA2FVHCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1721429741.USD","SG9999002224.SGD","BK4504","IE00BFTCPJ56.SGD","BK4139","IE00BJT1NW94.SGD","LU0058720904.USD","IE00BJJMRZ35.SGD","ABT","LU0266013472.USD","LU2237957811.SGD","EXAS","LU2112291526.USD","BK4585","LU0234572021.USD","SGXZ41872573.SGD","LU1989763427.SGD","LU1691799644.USD","LU0122379950.USD","BK4581","LU2089984988.USD","SGXZ23171101.USD","LU2133065610.SGD","SG9999004303.SGD","LU2237957902.USD","LU1061106388.HKD","BK4592","LU2468319806.SGD","BK4548","LU0289739699.SGD","BK4082","IE0002141913.USD","LU0170899867.USD","IE00B4R5TH58.HKD","LU0882574055.USD","IE0009355771.USD","LU1023059063.AUD","LU2211815571.USD","IE00B2B36J28.USD","LU1861558580.USD","LU1861559042.SGD","BK4566","LU1057294990.SGD","BK4568","LU0868494617.USD","LU1721429402.USD","LU0114720955.EUR","LU1914381329.SGD","SG9999002232.USD","BK4533"],"gpt_icon":0},{"id":"2595738496","title":"Exact Sciences Approves Accelerated Bonus and Equity Vesting for Executives Ahead of Abbott Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738496","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738496?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:34","pubTimestamp":1767015284,"startTime":"0","endTime":"0","summary":"Exact Sciences Corporation has approved new compensation arrangements for its named executive officers in connection with its pending merger with Abbott Laboratories. Under the approved agreements, executive officers will receive accelerated vesting and payment of their fiscal year 2025 annual bonuses, with performance deemed at 115% of target. Additionally, certain restricted stock unit  and performance share unit  awards granted prior to the merger agreement will vest early, with PSU awards vesting at varying percentages of target based on their grant year. Specifically, CEO Kevin Conroy will receive an accelerated 2025 annual bonus of $436,056 and 713,931 shares subject to PSU awards, while CFO Jeff Elliott will receive an accelerated bonus of $507,150 and 63,099 RSU shares. Accelerated payments are subject to clawback if employment ends under certain circumstances, and executives may receive additional payments if actual performance exceeds the accelerated performance levels.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL4ZpmcN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","LU1061106388.HKD","LU2133065610.SGD","BK4581","LU1691799644.USD","LU2237957811.SGD","BK4504","BK4566","IE00BJT1NW94.SGD","LU2112291526.USD","BK4139","LU1057294990.SGD","IE0009355771.USD","EXAS","SGXZ23171101.USD","BK4585","LU1914381329.SGD","LU2089984988.USD","LU0114720955.EUR","LU0868494617.USD","BK4548","LU2324357040.USD","LU1721429741.USD","LU0122379950.USD","BK4082","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU0289739699.SGD","SG9999004303.SGD","LU0170899867.USD","LU2237957902.USD","LU0058720904.USD","LU1989763427.SGD","SG9999002224.SGD","LU0882574055.USD","BK4588","LU0234572021.USD","SG9999002232.USD","BK4568","BK4592","IE0002141913.USD","SGXZ41872573.SGD","LU1861558580.USD","ABT","IE00BJJMRZ35.SGD","LU1721429402.USD","IE00B2B36J28.USD","LU1861559042.SGD","LU1023059063.AUD","BK4533"],"gpt_icon":0},{"id":"2592751181","title":"Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2592751181","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592751181?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:16","pubTimestamp":1766092609,"startTime":"0","endTime":"0","summary":"Exact Sciences Corporation has announced the enrollment of the first participant in the CRANE Study, a multi-center case-control clinical evaluation in Japan. The study, conducted in collaboration with Japan's National Cancer Center Hospital East, will assess the clinical performance of Exact Sciences' blood-based Multi-Cancer Early Detection  test. The CRANE Study aims to enroll approximately 2,000 participants nationwide, including both individuals with and without cancer, to evaluate the test’s sensitivity and specificity across multiple cancer types and stages. The results of the study have not yet been presented and will be reported in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLbLcWL8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU0266013472.USD","BK4139","LU1861559042.SGD","BK4588","BK4585","LU1861558580.USD","EXAS","LU2324357040.USD"],"gpt_icon":0},{"id":"2591612530","title":"Is Exact Sciences (EXAS) Still Undervalued After Its Recent Share Price Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612530","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591612530?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:18","pubTimestamp":1765779515,"startTime":"0","endTime":"0","summary":"Exact Sciences (EXAS) has quietly become one of the stronger movers in diagnostics this month, with shares climbing sharply as investors focus on its improving revenue growth and narrowing losses in cancer testing.\nSee our latest analysis for Exact Sciences.\nThat sharp 30 day share price return of over 50 percent builds on a powerful 90 day gain and a 67 percent one year total shareholder return. This is a clear sign that sentiment has swung toward Exact Sciences growth story despite its...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/is-exact-sciences-exas-still-undervalued-after-its-recent-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/is-exact-sciences-exas-still-undervalued-after-its-recent-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861559042.SGD","BK4548","EXAS","LU1861558580.USD","BK4585","BK4139","LU2324357040.USD","BK4588","LU0266013472.USD"],"gpt_icon":0},{"id":"2590423385","title":"Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590423385","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590423385?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:30","pubTimestamp":1765492215,"startTime":"0","endTime":"0","summary":"Exact Sciences Corporation has announced results from the first clinical study of its Oncodetect molecular residual disease  test in early triple-negative breast cancer . The data, presented at the San Antonio Breast Cancer Symposium , show that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early TNBC. The substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group as part of the NSABP-B-59/GBG-96-GeparDouze trial, evaluated circulating tumor DNA  in blood samples collected before treatment and after surgery. Results demonstrated the test's ability to help identify patients at higher risk of recurrence, supporting its potential role in informing post-surgical treatment decisions. Exact Sciences intends to submit the data for peer-reviewed publication and to MolDx in support of Medicare coverage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL59jZqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","BK4548","EXAS","BK4588","LU1861559042.SGD","LU2324357040.USD","LU1861558580.USD","BK4585","BK4139"],"gpt_icon":0},{"id":"2590428335","title":"Exact Sciences, the Nsabp Foundation, and the German Breast Group Present Results for the Oncodetect® Mrd Test in Early Triple-Negative Breast Cancer at Sabcs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590428335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590428335?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:30","pubTimestamp":1765492200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA6R76ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4585","BK4588","BK4548","EXAS","BK4139","LU0266013472.USD","LU2324357040.USD","LU1861558580.USD"],"gpt_icon":0},{"id":"2590511293","title":"Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511293","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511293?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:15","pubTimestamp":1765462522,"startTime":"0","endTime":"0","summary":"Illumina Inc. has announced a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company. The partnership aims to advance MyOme's Proactive Health  Trial, a large-scale clinical trial designed to demonstrate the benefits of using whole-genome sequencing combined with MyOme's AI-integrated risk models for early detection and prevention of common, chronic conditions, cancers, and rare diseases. Illumina's leading sequencing technology will be integrated with MyOme's advanced bioinformatics and risk models to deliver improved patient outcomes and significant healthcare cost savings. The collaboration also supports the expansion of MyOme's diagnostic products, including proactive health and rare disease tests, with the goal of providing more accurate, ancestry-relevant risk assessments for a wide range of diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLbfqk3z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXAS","LU0266013472.USD","LU1861558580.USD","BK4585","ILMN","LU1861559042.SGD","BK4534","LU2324357040.USD","BK4548","BK4535","BK4588","BK4121"],"gpt_icon":0},{"id":"2589499814","title":"Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589499814","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589499814?lang=en_us&edition=fundamental","pubTime":"2025-12-06 02:33","pubTimestamp":1764959580,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies shares fall as Natera's Foresight acquisition heightens MRD competition and tempers recent takeover speculation.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/05/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/05/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49238445/why-is-adaptive-biotechnologies-stock-trading-lower-after-nateras-over-400-million-deal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49238445/why-is-adaptive-biotechnologies-stock-trading-lower-after-nateras-over-400-million-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2468319806.SGD","LU0963586101.USD","LU1721429402.USD","BK4592","LU1861558580.USD","ABT","LU0012050646.USD","LU1861559042.SGD","LU0345770993.USD","LU2065731478.USD","LU2065171311.SGD","LU0114720955.EUR","BK4139","LU0868494617.USD","LU2237957811.SGD","LU0058720904.USD","LU1064131342.USD","SG9999004303.SGD","ADPT","SGXZ23171101.USD","BK4504","BK4588","LU2065169927.USD","LU2112291526.USD","LU2463526074.USD","EXAS","LU1989763427.SGD","LU1989763690.USD","LU0170899867.USD","LU2264538146.SGD","SGXZ41872573.SGD","IE00BJT1NW94.SGD","SG9999002232.USD","BK4566","BK4109","ASH","LU1914381329.SGD","IE00BFTCPJ56.SGD","LU2089984988.USD","NTRA","SG9999002224.SGD","BK4082","BK4568","BK4121","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0234572021.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2211815571.USD"],"gpt_icon":0},{"id":"2589890538","title":"Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2589890538","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589890538?lang=en_us&edition=fundamental","pubTime":"2025-12-05 19:37","pubTimestamp":1764934652,"startTime":"0","endTime":"0","summary":"Wondering if Abbott Laboratories is still worth buying after its long run as a healthcare blue chip, or if most of the upside is already priced in?\nDespite a modest slip of 2.4% over the last week and being roughly flat over 30 days, the stock is still up 10.5% year to date and over the past year, hinting that long term sentiment remains constructive at around $125.40 per share.\nRecent headlines have focused on Abbott’s continued push in medical devices and diagnostics, alongside regulatory...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-after-105-gains-and-dcf-pe-signals-amid-exa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-after-105-gains-and-dcf-pe-signals-amid-exa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","IE00B2B36J28.USD","LU1023059063.AUD","LU1061106388.HKD","ABT","BK4568","LU1989763427.SGD","BK4139","LU2211815571.USD","LU2237957902.USD","LU1691799644.USD","LU0868494617.USD","LU1721429402.USD","LU1861558580.USD","LU2468319806.SGD","LU0122379950.USD","SG9999004303.SGD","BK4581","LU2112291526.USD","IE00B4R5TH58.HKD","SG9999002224.SGD","IE00BJJMRZ35.SGD","BK4588","SGXZ23171101.USD","LU2133065610.SGD","LU2237957811.SGD","BK4592","LU0114720955.EUR","BK4566","LU0882574055.USD","BK4504","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1861559042.SGD","SGXZ41872573.SGD","IE00BJT1NW94.SGD","LU1721429741.USD","IE0002141913.USD","LU0289739699.SGD","LU0234572021.USD","LU2324357040.USD","EXAS","LU0170899867.USD","BK4533","LU1989763690.USD","LU1914381329.SGD","LU1057294990.SGD","LU0266013472.USD","DCF","SG9999002232.USD"],"gpt_icon":0},{"id":"2589283276","title":"Has Exact Sciences Rally of Over 50% Left Room for Further Upside?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589283276","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589283276?lang=en_us&edition=fundamental","pubTime":"2025-12-05 04:32","pubTimestamp":1764880326,"startTime":"0","endTime":"0","summary":"If you are wondering whether Exact Sciences is still a smart buy after its big run, or if you are late to the party, this breakdown will help you assess whether the current price reflects the company’s long term potential.\nThe stock has cooled slightly over the last week, down 0.2%. However, that follows a 51.2% jump over the last month, gains of 77.9% year to date, and 57.9% over the past year. This naturally raises questions about how much upside may remain.\nRecent moves have been driven...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/has-exact-sciences-rally-of-over-50-left-room-for-further-up","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/has-exact-sciences-rally-of-over-50-left-room-for-further-up","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0266013472.USD","LU2324357040.USD","BK4585","BK4548","LU1861559042.SGD","BK4139","DCF","LU1861558580.USD","BK4588","EXAS"],"gpt_icon":0},{"id":"2588326029","title":"REUTERS NEXT -Mizuho’s Katz sees 'fertile' conditions driving robust M&A market into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588326029","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588326029?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:51","pubTimestamp":1764791469,"startTime":"0","endTime":"0","summary":"REUTERS NEXT -Mizuho’s Katz sees 'fertile' conditions driving robust M&A market into 2026By Sabrina ValleNEW YORK, Dec 3 (Reuters) - The \"fertile\" conditions driving dealmaking in 2025 will persist th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL1N3X90VX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0957791311.USD","LU2764263203.CNY","EA","LU2211814178.USD","LU0950375773.USD","TMO","LU0868494617.USD","ABT","LU2125909593.SGD","LU0345770993.USD","LU1291159041.SGD","LU0985481810.HKD","LU2089984988.USD","SGXZ23171101.USD","BK4568","LU0994945656.USD","LU2298321311.HKD","LU1670628061.USD","LU0122379950.USD","BK4588","BK4599","BK4532","LU1691799644.USD","SG9999001176.USD","LU0006061336.USD","LU1057294990.SGD","IE0002270589.USD","LU1923621640.USD","LU0058720904.USD","LU2237957902.USD","MTSR","LU2357305700.SGD","EXAS","LU0456855351.SGD","LU0061474960.USD","LU0823417737.USD","LU1548497426.USD","BK4085","IE0002141913.USD","LU0306807586.USD","IE00B19Z8X17.USD","BK4566","BK4585","LU1720051108.HKD","LU1894683264.USD","LU2324357040.USD","BK4550","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2588334727","title":"Stifel Downgrades Exact Sciences to Hold From Buy, Adjusts Price Target to $105 From $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2588334727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588334727?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:33","pubTimestamp":1764592392,"startTime":"0","endTime":"0","summary":"Exact Sciences (EXAS) has an average rating of hold and mean price target of $101.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SF","EXAS"],"gpt_icon":0},{"id":"2587750818","title":"Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2587750818","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587750818?lang=en_us&edition=fundamental","pubTime":"2025-11-29 17:00","pubTimestamp":1764406839,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($EXAS) ), ( ($REGN) ), ( ($MRVL) ), ( ($FROG) ) and ( ($JAZZ) ). Here is a breakdown of their recent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/exact-sciences-regeneron-marvell-jfrog-jazz-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/exact-sciences-regeneron-marvell-jfrog-jazz-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FROG","BK4097","LU1861559042.SGD","LU2324357040.USD","LU0266013472.USD","BK4139","BK4588","LU1861558580.USD","LU1559883803.SGD","LU0566484027.USD","EXAS","BK4585","BK4548"],"gpt_icon":0},{"id":"2587773724","title":"Exact Sciences downgraded to Hold from Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2587773724","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587773724?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:00","pubTimestamp":1764363615,"startTime":"0","endTime":"0","summary":"Stifel downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $80, after the company announced an agreement to be a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exact-sciences-downgraded-to-hold-from-buy-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exact-sciences-downgraded-to-hold-from-buy-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","EXAS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exactsciences.com","stockEarnings":[{"period":"1week","weight":0.0036},{"period":"1month","weight":0.0085},{"period":"3month","weight":0.7503},{"period":"6month","weight":0.9671},{"period":"1year","weight":0.8015},{"period":"ytd","weight":0.0054}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.","yearOnYearQuotes":[{"month":1,"riseRate":0.52,"avgChangeRate":0.086643},{"month":2,"riseRate":0.28,"avgChangeRate":-0.066007},{"month":3,"riseRate":0.56,"avgChangeRate":0.070344},{"month":4,"riseRate":0.44,"avgChangeRate":0.019298},{"month":5,"riseRate":0.56,"avgChangeRate":0.062822},{"month":6,"riseRate":0.6,"avgChangeRate":0.087593},{"month":7,"riseRate":0.36,"avgChangeRate":-0.017914},{"month":8,"riseRate":0.44,"avgChangeRate":0.011727},{"month":9,"riseRate":0.52,"avgChangeRate":0.004142},{"month":10,"riseRate":0.36,"avgChangeRate":-0.033378},{"month":11,"riseRate":0.6,"avgChangeRate":0.038195},{"month":12,"riseRate":0.6,"avgChangeRate":0.05429}],"exchange":"NASDAQ","name":"Exact Sciences","nameEN":"Exact Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exact Sciences(EXAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exact Sciences(EXAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exact Sciences,EXAS,Exact Sciences股票,Exact Sciences股票老虎,Exact Sciences股票老虎国际,Exact Sciences行情,Exact Sciences股票行情,Exact Sciences股价,Exact Sciences股市,Exact Sciences股票价格,Exact Sciences股票交易,Exact Sciences股票购买,Exact Sciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exact Sciences(EXAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exact Sciences(EXAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction